Overview

A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (<=) 30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblasti

Status:
Active, not recruiting

Trial end date:
2022-10-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in pediatric participants with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LL) and T-cell ALL/LL as measured by the complete response (CR) rate.

Phase:

Phase 2

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Asparaginase
Cyclophosphamide
Cytarabine
Daratumumab
Doxorubicin
Mercaptopurine
Methotrexate
Pegaspargase
Prednisone
Vincristine